Your Catalyst to a Lucrative Business
drug, making some of the most expensive treatments for cancer more widely available in developing
countries. Under this initiative, WHO has focused on two essential drug rituximab (principally used for the
treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukaemia), and trastuzumab (for the
treatment of breast cancer).
Browse Details of Report @ https://www.hexaresearch.com/research-report/biosimilars-market
In terms of region, Europe dominates the market for biosimilars followed by North America. The
dominance of Europe is due speedy approval of the drug by European regulatory bodies. Furthermore,
improving healthcare infrastructure and ageing population is expected to drive the market over the
forecast period. However, Asia Pacific is projected to be the fastest growing region owing to the
increasing disposable income of middle-class families, growing medical tourism and improving
healthcare infrastructure. Furthermore, increasing investment in R&D activities by pharmaceutical
giants is expected to boost the market in the projected period.
Hexa Research has segmented the global biosimilars market based on indication and region:
Segmentation by indication, 2014 - 2024 (USD Million)
• Blood Disorders
• Oncology
• Chronic & Autoimmune Diseases
• Others
Segmentation by region, 2014 - 2024 (USD Million)
• North America
• U.S.
• Europe
• Germany
• Asia Pacific
• China
• India
• Japan
• Rest of the world
Key players analyzed:
• Dr. Reddy’s Laboratories Ltd
• Mylan
• Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
• Pfizer Inc.
• Sandoz International GmbH
• Teva Pharmaceuticals Industries Ltd.
• Amgen Inc.
• STADA Arzneimittel AG
Follow Us: